SCHEMBL7229899

SCHEMBL7229899

NC=Cc1ccc2c(c1)OCCO2

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.59
CYP19A1 P11511 2/20 0.53
CYP3A4 P08684 1/20 0.52
ATM Q13315 1/20 0.52
RAB9A P51151 7/20 0.51
MAPT P10636 6/20 0.51
NPC1 O15118 4/20 0.51
NPSR1 Q6W5P4 1/20 0.50
CXCL12 P48061 1/20 0.49
DYRK1A Q13627 1/20 0.47
DYRK2 Q92630 1/20 0.47
DYRK1B Q9Y463 1/20 0.47
ALDH1A1 P00352 3/20 0.46
HSD17B10 Q99714 2/20 0.46
HPGD P15428 2/20 0.46
TDP1 Q9NUW8 1/20 0.46
GSK3B P49841 1/20 0.45
MTOR P42345 1/20 0.45
VCP P55072 1/20 0.45
KMT2A Q03164 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4447863 0.88 CYP19A1 (0.68) KDM4ECYP19A1CYP3A4ATMRAB9A
SCHEMBL2094645 0.80 KDM4E (0.59) KDM4ECYP19A1CYP3A4ATMRAB9A
SCHEMBL2094647 0.80 KDM4E (0.59) KDM4ECYP19A1CYP3A4ATMRAB9A
SCHEMBL11492405 0.79 KDM4E (0.54) KDM4ECYP19A1CYP3A4ATMRAB9A
SCHEMBL11492404 0.79 KDM4E (0.54) KDM4ECYP19A1CYP3A4ATMRAB9A
SCHEMBL11486121 0.77 KDM4E (0.60) KDM4ECYP19A1CYP3A4ATMRAB9A
SCHEMBL11486125 0.77 KDM4E (0.60) KDM4ECYP19A1CYP3A4ATMRAB9A
SCHEMBL30837170 0.77 KDM4E (0.60) KDM4ECYP19A1CYP3A4ATMRAB9A
SCHEMBL11488915 0.76 KDM4E (0.54) KDM4ECYP19A1CYP3A4ATMRAB9A
SCHEMBL13978818 0.76 KDM4E (0.54) KDM4ECYP19A1CYP3A4ATMRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6509344-B1 A method for treating a patient having cancer, said method comprising the step of administering to the patient an effective amount of a compound according to claim 1, whereupon said patient is treated for cancer, and wherein the cancer is THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES 2003-01-21 US disclosed